Fact

Sheet
November 2016

Mission:
Together with our customers,
we are driven to make healthcare better.

Stryker is one of the world’s leading medical technology

companies and, together with our customers, we are driven
to make healthcare better. The Company offers a diverse
array of innovative products and services in Orthopaedics,
Medical and Surgical, and Neurotechnology and Spine that
help improve patient and hospital outcomes. Stryker is active
in over 100 countries around the world. Please contact us for
more information at stryker.com.

Investor Contact Media Contact

Katherine A. Owen Charles DeCoster IV, MSA Yin C. Becker
Vice President, Strategy and Assoc. Manager, Investor Relations Vice President, Communications
Investor Relations and Strategy and Public Affairs
katherine.owen@stryker.com charles.decoster@stryker.com yin.becker@stryker.com
269 385 2600 269 389 7421 269 385 2600
 Organic revenue growth1

At a 5.1%
5.8%
4.6%
6.1%

Glance 2.4%
2.9%

Stryker

MedTech Market 2

100+ 2013

Capital allocation
2014 2015

countries where 2013-2015 Capital Deployment History

Stryker products
are sold Dividends: $1.4B M & A: $3.4B
Committed to increasing Focused on driving
the dividend at or sales growth in core
above EPS growth and adjacent markets

36 Share Repurchases:
$1.1B
straight years of
Continued share
sales growth buybacks over time

2015 geographic sales

4,898 Emerging
Markets:
United
States:
72%
patents owned 7%
globally $9.9B
International
(Developed):

~33,000
21%

employees worldwide Adjusted diluted net Adjusted return on

earnings per share 3 $5.12 invested capital 4
$4.73
$4.49
16.0% 2013

15.5% 2014

2013 2014 2015 15.6% 2015

1 Organic revenue growth removes the impact of changes in foreign currency exchange rates and the first twelve months of acquisition sales
that affect the comparability and trend of sales.
2 Data Source: Company analysis of 16 peer companies.
3 Non-GAAP financial measure. These measures exclude intangible amortization from earnings in all periods (reference the reconciliation of
GAAP to non-GAAP in the Financial Summary).
4 Return on Invested Capital: adjusted net earnings less interest expenses net of tax / (average total debt and total equity)

2
Stryker’s
International growth
Stryker has a significant opportunity

core strategies
to grow international market share
through all of its current business
offerings. Stryker will accomplish
this by leveraging its broad product
Leading player in medtech portfolio and services, by continuing
to capture market share in key
Stryker is a broadly diversified medical technology company with no single
business in any segment representing more than 15 percent of total Stryker developed markets and building scale
revenue. This balanced diversity provides steady growth and enables the Company in emerging markets.
to pursue market opportunities in many promising areas.
Stryker has shown success in Europe,
Spine: 7% with a growth rate that now exceeds
Sustainability solutions: 2%
the market. This shift in execution
Medical: 8% Neurovascular: 5%
was driven primarily by initiation of
Endoscopy: 14% Neuro powered the Trans Atlantic Operating model
instruments: 3%
Instruments: 15% and the creation of the European
Craniomaxillofacial: 3%
regional headquarters. This growth
is sustainable, due to the under-
penetration relative to US share, in a
2015 Knees: 14% similar customer environment against
Sales the same competitors.

Emerging markets continues to

Hips: 13% represent a significant opportunity.
Other: 3%
Trauma & extremities: 13% Stryker is diversifying its offering
in these geographies by adding
a value segment offering along
with its premium products. These
Business unit specialization markets have shown some macro
Styker’s business units contain dedicated sales, business development, marketing level softness, but Stryker remains
and research & development functions. These critical links and proximity to the committed to investing there for the
specialized customer allow rapid identification of customer needs and the agility to longterm.
address those needs.
Cost transformation
This organizational structure is the key to driving market share gains and category Stryker sees significant
leadership. Above market R&D spending and the specialized focus of that spending opportunities to drive meaningful
results in healthy product pipelines across all business, which will allow for the operating leverage through its
consistency of future growth. Cost Transformation for Growth
(CTG) initiative. This includes:
Acquisitions product line rationalization,
The 40+ acquisitions that Stryker has closed on over the last 5 years bolster its indirect procurement, a common
ability to consistenly grow at the high end of medtech. While Stryker has continued ERP platform, expansion of shared
to diversify its portfolio, it remains focused on three key hosptial service lines: services and continued plant network
Orthopaedics, Neurotechnology and Specialty Surgery. In the “win big, lose big” optimization. These initiatives, in
environment created by continued hospital consolidation, category leadership will combination with our continued
become increasingly important. That said, Stryker does not believe that hospitals peer leading growth, will deliver
are likely to purchase across service lines, even in the long term. sustainable shareholder value into
the forseeable future.
Even with the high volume of activity over the recent years, Stryker remains well
positioned to continue to add to its portfolio through acquisitions. The target
identification approach continues to be driven by the specialized business units,
and the size of the deals are likely to be similar to what has been seen by Stryker
historically. That is, a regular volume of smaller tuck-in deals, puctuated with some
larger acquisitions.

3
 Orthopaedics
43% of total company sales
Financial and market information reflects 2015 results
Hip replacements
Market Market Market
size position share
$5.8B #3 22%
Stryker offers a comprehensive portfolio
of solutions for primary and revision
hip arthroplasty. The Hip business
continues to drive the innovation in
clinically successful product lines
including Accolade, Exeter and X3.
Stryker utilizes SOMA, a proprietary
analytics system to design and
validate implants for optimized fit
and performance. Stryker’s hips are
designed to accommodate the wide
variety of surgical approaches used in
today’s evolving industry.
Accolade II with
MDM Hip System
4
Knee replacements
Market Market Market
size position share
$7.2B #3 20%
Stryker offers a complete portfolio
of implants and systems designed to
provide surgeons with multiple options
to treat patients with osteoarthritis.
Since its launch in 2004, the Triathlon
single-radius design has helped restore
function and relieve pain for over
1 million patients. Stryker’s knees are
designed to work with the body to
promote a natural-like circular motion.
The Company’s Triathlon Primary and
Revision Knee implants and instruments
allow orthopaedic surgeons to address
a wide variety of clinical situations
that may arise during complex knee
surgeries.
Triathlon Tritanium
Total Knee System
Trauma & extremities
Market Market Market
size position share
$8.2B #2 16%
Stryker is a leading supplier of trauma
and extremities products for the
surgical treatment of bone fractures,
abnormalities and diseases. The
portfolio features a comprehensive
array of intramedullary nails,
external fixation, locking plates, bone
substitutes and joint solutions. Its
commitment to innovation, dedication
and education benefits orthopaedic
trauma surgery by helping surgeons to
enhance surgical treatment and serve
individual patient needs.
Gamma3
Trochanteric Nail

Foot & ankle
Market Market Market
size position share
$1.2B #2 18%
Stryker offers a comprehensive
portfolio of products for foot and ankle
surgical treatment of bone fractures,
deformities and diseases. The product
line consists of plating systems, screw
systems, nitinol implants, external
fixation, soft tissue, total ankle
replacement and biologics. Always
striving for innovation, the foot and
ankle business offers products such as
SonicAnchor, STAR total ankle, VariAx
2 and Fixos 2. The team consists of
highly trained professionals who advise
surgeons allowing them to implant
with confidence to achieve excellent
clinical outcomes.
Foot & Ankle
es
mi
ma & extre
u
Tra
Other joint
replacement
Robotic-arm
assisted technology
The Mako platform brings value to
joint replacement surgery through
procedural advancements and an
enhanced patient experience focused
on clinical outcomes. Mako’s Robotic-
Arm Assisted Technology enables 3D
preoperative planning and provides
surgeons intra-operative stereotactic
feedback for bone preparation
and implant placement. Surgeon-
controlled intra-operative adjustments
can be made to optimize implant
placement during surgery.
Bone cement
With over 50 years of clinical history,
more than 600 published studies and
currently the top-selling bone cement
in the world,2 the Simplex family of
bone cements continue to provide
clinically-backed fixation.
Mako Robotic-Arm
Assisted
Technology
er
O th
Kn
ti
ee
s
Sales
$4.2B
H i ps
Performance
Solutions
Stryker’s Performance Solutions
partners with hospitals and physician
groups to create exceptional patient
experiences, proven quality outcomes
and sustainable profitability. It
provides customers the performance
intelligence they need to understand
and benchmark their orthopaedic
services and physician practices. With
this intelligence the business helps
them plan for alignment strategies
that will enable them to turn reform
into opportunity and build customized
implementation programs that help
deliver patient-centric care and quality
outcomes.
 Global Markets for Bone Cement and
2
Accessories 2012 - US, Europe (France,
Germany, Italy, UK), Japan, Brazil, India,
China. Millennium Research Group,
December 2011.
JointCoach
5
 MedSurg
39% of total company sales
Financial and market information reflects 2015 results
Instruments
Market Market Market
size position share
$5.5B #1 35%
Stryker is a leader in creating products
that make surgery more efficient,
reduce trauma and improve techniques.
The Company is known for a wide
range of innovative operating room
products, from leading surgical power
tools to personal protection and waste/
fluid management. Stryker’s goal is
to improve the surgical and patient
experience by developing products that
are more reliable and less complicated
to use.
Stryker’s computer assisted surgery
technology focuses on procedural
simplification and workflow
flexibility, and enables surgeons to
accurately track, analyze and monitor
instrumentation relative to a patient’s
anatomy during surgical procedures to
enhance patient outcomes.
Stryker NAV3i
Platform
6
Medical
Market Market Market
size position share
$7.0B #2 12%
Stryker Medical partners with
healthcare providers by providing
holistic solutions that focus on
improving caregiver and patient
outcomes. Stryker Medical is
dedicated to innovation and thoughtful
design, offering a broad portfolio of
products including but not limited
to: hospital beds and stretchers,
surfaces, powered ambulance cots and
fasteners, temperature management
solutions, interconnected technologies,
and hospital room furniture. The
Medical division of Stryker strives to
improve caregiver and patient safety,
prevention, and efficiency, delivering
proven clinical/financial outcomes and
confident care.
Stryker S3
Med/Surg Bed
Sustainability
Solutions
Market Market Market
size position share
$0.3B #1 61%
Medical device reprocessing and
remanufacturing is good for the
environment and a hospital’s bottom
line. Stryker’s Sustainability Solutions
provides custom solutions to optimize
both of these goals.
As the trusted supplier of choice for
roughly 3,000 U.S. Hospitals, including
nearly all of US News & World Report’s
“Best Hospitals,” our approach is
simple: grow a hospital’s financial and
environmental sustainability. In 2015,
Sustainability Solutions’ reprocessing
programs helped customers save $262
million in supply costs and divert
12.3 million pounds of waste from
landfills. Together with our customers,
we can enhance patient care without
compromising quality or safety.
Reprocessed
LigaSure LF1637
 n a bili t y
st a i
Su olutions
s

l
ca

In
di

st r
Me

um
Sales

e n ts
$3.9B

Endoscopy
En
do
s co
py

Endoscopy Communications Sports medicine

Market Market Market Market Market Market Market Market Market
size position share size position share size position share

$4.0B #2 21% $1.4B #2 19% $4.2B #4 7%

As a technology leader in minimally
invasive surgery, Stryker offers
comprehensive solutions to meet
the changing needs of the high-tech
operating room. These solutions
combine voice activation, infrared
imaging and high-definition video
technology with a market leading data
management system to offer a surgical
environment designed to improve
patient outcomes.
Stryker focuses on optimizing efficiency
in operating rooms and surrounding
care environments. We leverage our
highly capable sales and service teams,
our configurable product portfolio, and
a wide range of connectivity options to
help our customers design, equip, and
connect their ideal work spaces. OR
integration systems, surgical video,
equipment management systems,
surgical lights, and surgical tables are
the foundational elements of our iSuite
solution.
Stryker offers a wide range of
innovative sports medicine implants,
instrumentation, resection and
biologic solutions. Our solutions focus
on minimally invasive and open
approaches to the shoulder, hip, knee
and small joints. From our flexible
technology and small peek implants
to our “tie-able” tape suture and
optimal cutters and burs, Stryker’s
Sports Medicine business delivers a
comprehensive and innovative portfolio
of products and business solutions to
help our customers excel, both clinically
and operationally.

1588AIM Platform iSuite ICONIX CinchLock

7
 Neurotechnology & Spine
18% of total company sales
Financial and market information reflects 2015 results
Neurovascular
Market Market Market
size position share
$1.7B #1 31%
Stryker is focused on advancing
the practice of less invasive stroke
therapies through its Complete Stroke
Care solutions. Stryker is dedicated
to providing innovative stroke
products and services for ischemic and
hemorrhagic stroke, and committed
to providing clinical education and
support to help physicians deliver
better patient outcomes. Products
include: stent retriever, detachable
coils, stents, balloons, guidewires and
microcatheters.
Target Coils Trevo XP ProVue
Retriever
8
Neuro powered
instruments
Market Market Market
size position share
$1.4B #2 24%
Stryker’s neuro, spine and ENT
portfolio includes a comprehensive
suite of products developed for the
fine tolerances required by these
surgical specialties. Continued product
innovation allows these specialty care
providers to improve their existing
surgical procedures, while exploring
new techniques to further advance
the clinical outcomes of their patients.
Products include electric and pneumatic
drill systems and accessories, an
ultrasonic aspiration device for soft
tissue removal and bone cutting, non-
stick bipolar forceps, bone mill and
bioresorbable nasal and ear dressings.
Signature
Portfolio
Craniomaxillofacial
Market
size
Market Market
position share
$1.1B #2 23%
Stryker is a market leader in products
used in maxillofacial, craniofacial
and neurosurgical procedures. Its
comprehensive product portfolio
is designed to provide innovative
solutions to healthcare providers
with the goal of improved surgical
outcomes. The craniomaxillofacial
product line features bone fixation
systems, biomaterials, porous
polyethylene implants, microdissection
needles and surgical instrumentation
to address a wide variety of surgical
specialties and procedures.
DirectInject
 io -
an a c i a l
C r illo f
ax

M
Neustrument ed

S pi
s
ro power
Sales

ne
$1.8B

in
Spine
Ne
ur o
vascular
Market Market Market
size position share

$9.0B #4 8%

Spinal implants Interventional spine

Stryker offers one of the most
comprehensive and diverse product
portfolios for the treatment of
degenerative and complex spinal
disorders.  The Company is committed
to developing technologies for
traditional and minimally invasive
surgical techniques, enabling surgeons
to help their patients return to a more
active lifestyle.  Products include
implants, instruments and biologics
solutions for the cervical, thoracic and
lumbar spine.
The Interventional Spine business
focuses on providing an extensive
and innovative product portfolio
for vertebral augmentation,
vertebroplasty and radiofrequency
ablation procedures, along with a
diagnostic tool and decompression
treatment advances for contained disc
herniations.

Tritanium PL Aero-C SafeWire iVAS Vertebral

Cage Augmentation
System

9
 M&A
to enhance portfolio
Concentric
Orthovita
2011
Memometal
Neurovascular
Recent acquisition highlights
Muka Metal, A.S.
Muka sells hospital beds, stretchers
and related patient room furniture and
accessories that serve markets across
Turkey and other regions globally.
Since launching its first hospital
bed in 2002, Muka has established
itself as a leading manufacturer and
marketer of hospital beds, stretchers
and related patient room furniture and
accessories. Muka aligns with Stryker’s
strategy to expand our global presence
through existing channels with an
established and trusted brand which
will bolster Stryker Medical’s bed and
stretcher offerings, and is a compelling
opportunity to drive growth in Turkey
and other regions around the world.
10
Trauson
Pivot Medical
2012 2013
Surpass MAKO
Sage Products
Sage Products is a leading developer
of innovative prevention products
and proprietary solutions designed
to improve outcomes for patients and
clinicians alike, while maximizing
efficiency and profitability for
healthcare facilities. Sage’s products
include solutions for oral care, skin
preparation and protection, patient
cleansing and hygiene, turning and
positioning devices and heel care boots.
Sage’s disposable products help reduce
“Never Events”, specifically hospital
acquired conditions and healthcare
worker injury. Together, Sage and
Stryker are now focused on offering
products and services that support a
mindset of prevention primarily in
the intensive care unit and MedSurg
hospital unit setting.
Patient Safety
Technologies
CoAlign
Innovations, Inc.
Berchtold
Holding
2014
Small Bone
Innovations
Synergetics USA
Stryker’s acquisition of Synergetics
USA, Inc.’s neuro portfolio includes
the Malis generator, Spetzler-Malis
disposable forceps and Stryker’s
existing SONOPET Ultrasonic Aspirator
tips and RF generator. Synergetics
USA, Inc.’s neuro portfolio is highly
complementary to Stryker’s Neuro,
Spine and ENT business and offers
an expanded neurosurgical product
offering. Stryker’s full portfolio of non-
stick bipolar forceps includes Spetzler-
Malis and SILVERGlide Bipolar Forceps.
Regardless of your preference for
single-use Spetzler-Malis or reusable
SILVERGlide Bipolar Forceps, you can
expect excellent visualization, precision
and control.
 Core Business
Adjacency
Vertebral Compression
Fracture Portfolio from BD

CHG Hospital Synergetics USA’s Ivy Sports

Beds Neuro Portfolio Medicine, LLC

SafeWire

2015 2016 2017

Sage Stanmore Implants

Products Worldwide

Muka Physio-Control
Metal International

Physio-Control International
Physio-Control is a leading global
provider of professional emergency
medical response solutions that
predict or intervene in life-threatening
emergencies for public access,
in hospital and out-of-hospital
use. Physio-Control develops,
manufactures and markets monitors/
defibrillators, automated external
defibrillators(AEDs), CPR-assist devices,
data management solutions, accessories
and disposables, technical support, and
implementation services. More than
one million Physio-Control supported
units are in use today in enterprise
companies, on fire rescue rigs,
ambulances and hospital crash carts—
protecting thousands of communities
worldwide. The acquisition expands our
global presence into emergency medical
care market and offers the opportunity
to impact a greater group of patients
across the continuum of care.
Vertical Compression Portfolio
This extensive, minimally invasive
line of vertebral augmentation
solutions includes, but is not limited
to, the AVAmax Plus mixing and
delivery system, AVAflex vertebral
balloon system, and their recent pre-
commercial announced 11G AVAflex
curved balloon and 13G AVAmax
vertebral balloons.
Stanmore Implants Worldwide
Stanmore Implants is an innovative
orthopaedic business focused on
serving the needs of surgeons that
treat adult and juvenile orthopaedic
oncology. Stanmore Implants’ portfolio
includes both patient specific and
off-the-shelf implant systems aimed
at limb salvage. The acquisition of
Stanmore Implants aligns with our core
joint replacement business to provide
differentiated technologies designed to
provide the most effective solutions for
orthopaedic oncology surgeons. This
addition expands our presence in the
global orthopaedic oncology market and
offers the unique opportunity to impact
a broader group of surgeons and their
patients globally.
SafeWire
The SafeWire portfolio, including the
Y-Wire guidewire and Tiger Needle
Family, is highly complementary to
Stryker’s spine product portfolio and is
aligned with the strategy of expanding
product offerings for minimally-
invasive spine surgery. The Y-Wire is
designed to mitigate potential wire-
based complications. With reduced
surgical steps and technical ease, it
also helps optimize workflow and
reduce patient and surgeon exposure to
fluoroscopy. This acquisition increases
Stryker’s competitive advantage as we
broaden our spine surgery product line
and extend our customer base.

11
 Financial
summary
($ in millions, except per share amounts) % of sales Yr/yr change

Results of operations 2013 2014 2015 2013 2014 2015 2013 2014 2015

Net sales $9,021 $9,675 $9,946 100% 100% 100% 4.2% 7.3% 2.8%
Cost of sales 3,002 3,319 3,344 33% 34% 34% 7.0% 10.5% 0.8%
Gross profit 6,019 6,356 6,602 67% 66% 66% 2.9% 5.6% 3.9%
Research, development and 536 614 625 6% 6% 6% 13.8% 14.6% 1.8%
engineering expenses
Selling, general and 3,467 3,547 3,610 38% 37% 36% 3.7% 2.3% 1.8%
administrative expenses
Recall charges, net of 622 761 296 7% 8% 3% - - -
insurance proceeds
Intangible asset 138 188 210 2% 2% 2% 12.2% 36.2% 11.7%
amortization
Total operating expenses 4,763 5,110 4,741 53% 53% 48% 15.9% 7.3% -7.2%
Operating income 1,256 1,246 1,861 14% 13% 19% -27.9% -0.8% 49.4%
Other income (expense) (44) (86) (126) 0% -1% -1% 22.2% 95.5% 46.5%
Earnings before income taxes 1,212 1,160 1,735 13% 12% 17% -28.9% -4.3% 49.6%
Income taxes 206 645 296 2% 7% 3% -49.4% 213.1% -54.1%
Reported net earnings 1,006 515 1,439 11% 5% 14% -22.5% -48.8% 179.4%
Adjusted net earnings $1,714 $1,810 $1,949 19% 19% 20% 4.0% 5.6% 7.7%

Diluted per share amounts

Reconciliation of GAAP to Non-GAAP results 2013 2014 2015 2013 2014 2015

Reported Net Earnings $1,006 $515 $1,439 $2.63 $1.34 $3.78

Acquisition and integration-related charges 72 65 24 0.19 0.17 0.06
Amortization of intangible assets 98 133 147 0.26 0.35 0.39
Restructuring-related charges 46 78 97 0.12 0.20 0.26
Regulatory and legal matters 63 - (46) 0.17 - (0.12)
Rejuvenate and other recall matters 460 628 210 1.20 1.65 0.55
Donation 15 - - 0.04 - -
Tax matters (46) 391 78 (0.12) 1.02 0.20
Adjusted Net Earnings $1,714 $1,810 $1,949 $4.49 $4.73 $5.12

($ in millions)

Capital allocation 2013 2014 2015 3 year total

Mergers & acquisitions1 $2,320 $916 $153 $3,389
Dividends 401 462 521 $1,384
Share repurchases 317 100 700 $1,117
Total $3,038 $1,478 $1,374 $5,890
Net of cash acquired
1

12
Financial
summary
($ in millions)

Consolidated condensed balance sheets 2013* 2014* 2015*

Assets
Cash and cash equivalents $1,339 $1,795 $3,379
Marketable securities 2,641 3,205 700
Accounts receivable (net) 1,518 1,572 1,662
Inventories 1,422 1,588 1,639
Other current assets 519 503 563
Total current assets 7,439 8,663 7,943
Property, plant and equipment (net) 1,081 1,098 1,199
Goodwill and other intangibles (net) 5,833 6,204 5,930
Other assets 1,030 1,293 1,151
Total assets $15,383 $17,258 $16,223
Liabilities and shareholders’ equity
Current liabilities $2,657 $4,461 $3,502
Other liabilities 956 977 980
Long-term debt, excluding current maturities 2,723 3,225 3,230
Shareholders’ equity 9,047 8,595 8,511
Total liabilities and shareholders’ equity $15,383 $17,258 $16,223

Consolidated condensed statements of cash flow 2013 2014 2015

Operating activities
Net earnings $1,006 $515 $1,439
Depreciation 169 190 187
Amortization of Intangible Assets 138 188 210
Other, net 573 889 (937)
Net cash provided by operating activities 1,886 1,782 899
Investing activities
Acquisitions, net of cash acquired (2,320) (916) (153)
Change in marketable securities, net 298 (729) 2,379
Purchases of property, plant and equipment (195) (233) (270)
Net cash (used in) provided by investing activities (2,217) (1,878) 1,956
Financing activities
Proceeds from borrowings, net 1,005 1,159 48
Dividends paid (401) (462) (521)
Repurchase of common stock (317) (100) (700)
Other financing 13 32 32
Net cash provided by (used in) financing activities 300 629 (1,141)
Effect of exchange rate changes on cash and cash equivalents (25) (77) (130)
Change in cash and cash equivalents ($56) $456 $1,584
*Includes retrospective application of ASU 2015-03 Interest-Imputation of
Interest: Simplifying the Presentation of Debt Issuance costs

13
 Stryker leadership team
Kevin A. Lobo M. Kathryn Fink Katherine A. Owen
Chairman and Chief Executive Officer Vice President, Chief Human Vice President, Strategy and
Resources Officer Investor Relations
Yin C. Becker
Vice President, Communications and David K. Floyd Bijoy N. Sagar
Public Affairs Group President, Orthopaedics Vice President, Chief Information Officer
Glenn S. Boehnlein Michael D. Hutchinson Timothy J. Scannell
Vice President, Chief Financial Officer General Counsel Group President, MedSurg and
Neurotechnology
Lonny J. Carpenter Graham A. McLean
Group President, Global Quality President, Asia-Pacific
and Business Operations

Other officers
Dean H. Bergy Irene B. Corbe William J. Cymbaluk
Vice President, Corporate Secretary Vice President, Internal Audit Vice President, Corporate Regulatory
Affairs and Quality Assurance
William E. Berry, Jr. David G. Furgason
Vice President, Corporate Controller Vice President, Tax Bronwen R. Taylor
Vice President, Compliance and
Jeanne M. Blondia
Risk Management
Vice President, Finance and Treasurer

Division presidents
Businesses Bradford L. Saar Laurence F.I. Hipkin
Medical Eastern Europe, Middle East, Africa
William J. Huffnagle
Joint Replacement Spencer S. Stiles Hiroyuki Saeki
Instruments Japan
Xavier Berling
Trauma & Extremities Brian J. White Scott MacNair
Sustainability Solutions Canada
Bradley W. Paddock
Spine Regions M. Brent Scott
Asia
Mark H. Paul Maurice Ben-Mayor
Neurovascular South Pacific Fabrizio Signorin
Latin America
J. Andrew Pierce Stuart Silk
Endoscopy EMEA and Latin America

Additional information
Independent Registered Public Shareholders needing information Stock Listing
Accounting Firm regarding their certificates or dividends The Company’s common stock is traded
Ernst & Young LLP should contact: on the New York Stock Exchange under
Grand Rapids, Michigan American Stock Transfer & the symbol SYK.
Trust Company, LLC
Transfer Agent and Registrar Operations Center
American Stock Transfer & Trust 6201 15th Avenue, New York, NY 11219
Company, LLC 800 937 5449 | info@amstock.com
New York, New York

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Accolade,
AccuLIF, Aero, Cinchlock, ES2, Exeter, Gamma3, Gaymar, Hoffmann, ICONIX, Isolibrium, iSuite, iVAS, MAKOplasty, MAKO Surgical Corp., MDM, MEDPOR,
Memometal, NAV3i, Neptune, Orthovita, ReUnion, RIO, SafeWire, SDC3, SILVERGlide, Simplex, Small Bone Innovations, SmartLock, SOMA, Sonopet, STAR,
Stryker, Surpass, Target, Together with our customers, we are driven to make healthcare better., Trevo, Triathlon, Tritanium, Y-Wire, X3. All other trademarks are
trademarks of their respective owners or holders.
AVAflex and AVAmax are registered trademarks of Carefusion 2200, Inc.

14
Notes

15
 Stryker Corporation
2825 Airview Boulevard
Kalamazoo, Michigan 49002
269 385 2600

CP-BR-12, 08-2016